Elevance Health Inc. (ELV): BCG Matrix [June-2026 Updated]

This ready-made BCG Matrix Analysis of Elevance Health, Inc. Business gives you a clear, research-based view of where the portfolio is growing, generating cash, under pressure, or still uncertain-covering Carelon's $71.7 billion FY 2025 revenue, 22 million-member AI rollout, 45.4 million Health Benefits members, the $935 million CMS accrual, and the Medicaid/ACA drag shaping performance. It helps you quickly understand which units are acting as Stars, Cash Cows, Question Marks, and Dogs, and how market growth, relative strength, and capital allocation are influencing Elevance's strategy, margins, and future investment priorities.

Elevance Health, Inc. - BCG Matrix Analysis: Stars

Carelon sits in the Star quadrant because it combines rapid revenue expansion with continued strategic investment. FY 2025 revenue reached $71.7 billion, rising 33% from 2024, and Q1 2026 operating revenue climbed to $18.0 billion, up 7.9% year over year. The adjusted operating margin of 4.8% in Q1 2026 was down 100 basis points, reflecting deliberate reinvestment to support scale, integration, and capacity expansion. Growth continues to be driven by risk-based solutions and CarelonRx product revenue, while management has stated that Carelon Services is expanding risk-based capabilities to manage a larger share of healthcare spending.

AI adoption is another Star attribute because Elevance is scaling a capability that directly improves engagement, operating efficiency, and clinical workflow. In December 2025, the company rolled out its AI virtual assistant to 22 million commercial members through Sydney Health. By April 2026, more than 60,000 employees were using internal AI tools for productivity, including automated call summarization. Elevance also disclosed that it spends $1 billion annually on digital and AI capabilities, which highlights the size of the commitment behind this growth platform.

The operational impact of AI is already visible. Internal AI tools have reduced prior authorization denials by nearly 70% through the Health OS platform, signaling a measurable improvement in administrative performance and member experience. Management plans to expand the assistant to Medicare members in late 2026, which extends the growth runway and supports a Star classification rather than a mature, cash-generating position.

• 22 million commercial members reached through Sydney Health AI assistant
• 60,000+ employees using internal AI productivity tools by April 2026
• $1 billion annual investment in digital and AI capabilities
• Nearly 70% reduction in prior authorization denials through Health OS
• Medicare expansion planned for late 2026

RX volume expansion further strengthens the Star profile. CarelonRx adjusted scripts increased 7% to 340.7 million in FY 2025, indicating strong utilization across pharmacy-related services. That increase came alongside Carelon's 33% revenue growth to $71.7 billion, showing that the segment is scaling both in top-line contribution and transaction volume. In Q1 2026, Carelon revenue rose to $18.0 billion, and product revenue was identified as a quarter driver, reinforcing that the segment is not only expanding but also deepening its revenue mix.

The current margin profile suggests a business still in growth mode. A 4.8% adjusted operating margin is modest for a segment at this scale, but the lower margin is consistent with investment in infrastructure, product rollout, and capacity to support future earnings power. The fact that CFO Mark Kaye took direct oversight of Carelon from February 2026 underscores the importance of this growth engine within Elevance's portfolio and indicates disciplined financial focus on scaling returns.

Leadership changes also support the Star thesis by aligning execution with growth priorities. On March 31, 2026, Elevance named Kristy Duffey president of Carelon Health and William Fleming chief growth and strategy officer for Carelon. The company also appointed Darrell Oliveira as Carelon CFO and Jeff Plante as CFO for the Health Benefits segment. Earlier, Mark Kaye expanded his CFO role on February 26 to include direct oversight of Carelon. These moves indicate a deliberate push to strengthen governance, accelerate decision-making, and coordinate insurance and health services under a more integrated operating model.

• Kristy Duffey appointed president of Carelon Health
• William Fleming appointed chief growth and strategy officer for Carelon
• Darrell Oliveira named Carelon CFO
• Jeff Plante named CFO for Health Benefits
• Mark Kaye expanded CFO oversight to include Carelon

That leadership structure is consistent with a high-growth Star rather than a standalone mature asset. It places financial control, strategy, and operational execution in a tighter framework to support scale, improve mix, and expand the share of healthcare spending managed through Carelon. The combination of fast revenue growth, rising script volumes, heavy AI investment, and leadership alignment gives Elevance a Star platform with clear momentum across services, pharmacy, and digital care delivery.

Elevance Health, Inc. - BCG Matrix Analysis: Cash Cows

Elevance Health fits the Cash Cows quadrant through its massive, mature membership base and highly predictable premium stream. FY 2025 ended with 45.2 million Health Benefits members, and medical membership in Q1 2026 edged up to 45.4 million. Operating revenue reached $197.6 billion in FY 2025, up 13% from 2024, then rose another 1.5% to $49.5 billion in Q1 2026. The company also raised FY 2026 adjusted diluted EPS guidance to at least $26.75, above the January view of $25.50, while reaffirming operating cash flow of at least $5.5 billion.

The shareholder return profile reinforces the Cash Cow classification. Elevance returned $4.1 billion to shareholders in 2025 through dividends and share repurchases. In Q1 2026, it repurchased 3.7 million shares for $1.1 billion at an average price of $304.68, leaving $5.6 billion of repurchase authorization remaining as of March 31, 2026. The company also declared a $1.72 quarterly dividend for Q2 2026, payable June 25. These payouts are funded by the company's mature insurance base rather than by heavy incremental capital requirements.

• $4.1 billion returned to shareholders in 2025
• 3.7 million shares repurchased in Q1 2026
• $1.1 billion deployed for buybacks in the quarter
• $5.6 billion remaining authorization as of March 31, 2026
• $1.72 quarterly dividend declared for Q2 2026

Retention and quality metrics show why the business remains resilient. Elevance reported that 53% of its members were in 4-plus-star Medicare Advantage plans for 2026, up from 40% in 2025. That improvement helps defend a large installed book even as the market tightens. The Q1 2026 benefit expense ratio improved to 86.8% from 90.0% in FY 2025, while adjusted diluted EPS for the quarter came in at $12.58, beating estimates by $1.69. These figures indicate a mature operating model that still converts scale into earnings and cash.

Working capital discipline adds another layer of Cash Cow behavior. Days in claims payable increased to 46.6 days in Q1 2026, up 5.3 days from December 31, 2025, providing short-term funding support across a very large premium and claims base. Q1 2026 operating expense ratio was 12.8%, even after a $935 million regulatory accrual. FY 2025 adjusted diluted EPS still reached $30.29 despite being 8.3% below 2024, showing that the franchise continues to generate substantial cash even under margin pressure.

• Days in claims payable: 46.6 days in Q1 2026
• Increase from December 31, 2025: 5.3 days
• Q1 2026 operating expense ratio: 12.8%
• Regulatory accrual in Q1 2026: $935 million
• FY 2025 adjusted diluted EPS: $30.29
• FY 2025 EPS decline versus 2024: 8.3%

Elevance's Cash Cow position is supported by the combination of scale, recurring reimbursement flows, improved quality scores, and disciplined capital returns. The business does not rely on rapid expansion to generate value; instead, it monetizes a large, established membership base and converts that base into consistent operating cash flow, dividends, and buybacks.

Elevance Health, Inc. - BCG Matrix Analysis: Question Marks

Elevance Health's question-mark businesses are the parts of the portfolio that carry meaningful growth potential but still face uncertainty in conversion, regulation, execution, or monetization. They are capital-intensive or strategically important, yet they have not reached the scale or market dominance needed to move confidently into the star or cash-cow categories.

MEDICARE ADVANTAGE UNCERTAINTY. CMS notified Elevance on February 27, 2026 of intended sanctions that would suspend new enrollment in certain Medicare Advantage plans, and the company stated the suspension date was later extended to May 30, 2026. Elevance booked a $935 million accrual in Q1 2026 to reflect the estimated exposure. This matters because the Medicare Advantage business is a meaningful growth lever, but the regulatory disruption introduces immediate membership volatility. Management also expects Medicare Advantage membership to decline in the high-teens percentage range in FY 2026, which signals pressure on scale even as the company works through quality remediation.

There is still some protection from the quality side: 53% of members sit in 4-plus-star plans, which supports the franchise's competitive standing and helps offset some of the rating risk. Still, quality strength does not eliminate the commercial damage from enrollment suspension and lower growth. In BCG terms, the business has attractive market appeal, but the current market share trajectory is unstable, making it a classic question mark rather than a star.

CARELON HEALTH BUILD OUT. Elevance appointed Kristy Duffey, formerly of Optum, as president of Carelon Health on March 31, 2026, giving the division more focused leadership for clinical strategy across primary care and home care. The move is strategically important because Carelon is a key platform for integrating care delivery, utilization management, pharmacy, and home-based services. Yet the business is still in a development phase where scale does not automatically translate into dominance.

Carelon's FY 2025 revenue base reached $71.7 billion, but its adjusted operating margin was only 4.8%. That margin level indicates room for investment and operational expansion, but it does not yet show the kind of profitability typically associated with an entrenched market leader. Q1 2026 Carelon revenue was $18.0 billion, up 7.9%, which confirms momentum; however, the segment is still being built and optimized. Its service mix is strategically valuable, but it remains too early to classify it as a cash cow.

• FY 2025 Carelon revenue: $71.7 billion
• FY 2025 adjusted operating margin: 4.8%
• Q1 2026 revenue: $18.0 billion
• Q1 2026 revenue growth: 7.9%
• New leadership: Kristy Duffey, appointed March 31, 2026

AI MONETIZATION PATH. Elevance's digital and AI stack is already operating at scale: the Sydney Health AI assistant reaches 22 million commercial members, and internal AI tools are used by more than 60,000 employees. The company says it spends $1 billion annually on digital and AI capabilities, making this one of its most visible strategic investment areas. These tools have helped reduce prior authorization denials by nearly 70%, a strong signal of process improvement and member/provider experience enhancement.

Even so, the AI platform has not yet become a distinct revenue engine. The benefits are currently concentrated in efficiency, productivity, and service quality rather than in direct monetization. Management plans to extend the assistant to Medicare members in late 2026, which could broaden reach significantly, but as of June 2026 the platform is still a scaling bet. In BCG terms, this is high-upside optionality with uncertain revenue conversion, which places it squarely in the question-mark category.

GOVERNMENT BUSINESS REFORM. On March 31, 2026, Elevance centralized Medicare, Medicaid, and federal solutions under one President of Government Business to improve accountability and align execution across public programs. The restructuring came after Medicaid attrition had already reduced FY 2025 membership to 45.2 million. That membership pressure shows the segment is operating in a difficult environment, shaped by redeterminations, regulatory changes, and uneven retention trends.

At the same time, management framed 2026 as a year of execution and repositioning aimed at restoring 12% adjusted EPS growth by 2027. That target is ambitious, but the business is not yet demonstrating the clean demand momentum or durable enrollment expansion needed to rank as a star. The regulatory freeze, enrollment instability, and mixed membership outcomes keep the government platform in transition. Its scale is large, but its growth path remains uncertain.

• Government business unified under one President on March 31, 2026
• FY 2025 Medicaid membership: 45.2 million
• Management target: 12% adjusted EPS growth by 2027
• 2026 internal framing: year of execution and repositioning
• Key constraint: regulatory freeze and membership attrition

Across these areas, Elevance's question marks share a common profile: they are strategically important, investment-heavy, and capable of generating stronger returns later, but they currently lack the market certainty required for cleaner BCG classification. Medicare Advantage is exposed to sanctions and enrollment pressure, Carelon Health is still proving operating leverage, AI is improving efficiency without yet producing direct revenue scale, and the government business is in restructuring mode amid membership instability.

Elevance Health, Inc. - BCG Matrix Analysis: Dogs

Elevance Health's weakest BCG profile appears in its lower-growth, lower-return insurance exposures, especially Medicaid and certain ACA-related blocks, where membership pressure and medical cost inflation have outweighed revenue growth. FY 2025 membership declined 1.1% to 45.2 million, with Medicaid attrition named as a key driver. At the same time, the company's Q4 2025 benefit expense ratio rose to 93.5%, up 110 basis points year over year, while the FY 2025 benefit expense ratio increased to 90.0% from 2024. Those figures point to a mature, pressured book that is consuming resources without producing strong margin expansion.

The Medicaid exposure fits the dog quadrant because it combines scale with weak returns rather than growth with attractive economics. Elevance explicitly pointed to competitive pressure in Medicaid as a margin headwind, and that pressure showed up in the benefit expense ratio trajectory. When a large membership base is shrinking and the medical cost ratio is rising at the same time, the business behaves like a cash-consuming legacy asset rather than a growth engine.

ACA cost pressure reinforces the same conclusion. In Q4 2025, the 93.5% benefit expense ratio reflected higher medical costs in both Medicaid and ACA plans. FY 2025 adjusted diluted EPS still fell 8.3% to $30.29 even though operating revenue rose 13% to $197.6 billion, showing that top-line growth did not translate into bottom-line leverage. Elevance also noted that Inflation Reduction Act changes to Medicare Part D increased seasonality and cost trends across the book, adding another layer of expense volatility.

• FY 2025 operating revenue: $197.6 billion, up 13%
• FY 2025 adjusted diluted EPS: $30.29, down 8.3%
• Q4 2025 benefit expense ratio: 93.5%
• FY 2025 benefit expense ratio: 90.0%
• FY 2025 membership: 45.2 million, down 1.1%

The regulatory cost burden creates another dog-like profile because it absorbs cash without supporting sustainable growth. In Q1 2026, Elevance recorded a $935 million regulatory accrual related to the CMS matter, and the operating expense ratio reached 12.8% in the same quarter. Even though adjusted EPS of $12.58 beat estimates, the charge reduced flexibility and kept the affected book under pressure. The enrollment suspension extended to May 30, 2026, which prolongs the drag on the segment and limits near-term recovery.

Low-return legacy mix is the broader theme behind the dog classification. The insurance portfolio's FY 2025 benefit expense ratio rose to 90.0% from 2024, and Q4 2025 worsened to 93.5%, signaling that a meaningful share of the mature Health Benefits business is not generating strong underwriting economics. Management's response has centered on pricing discipline, utilization management, and cost control rather than aggressive expansion, which is typical when a segment must be defended rather than scaled.

Elevance's lower-quality blocks are therefore characterized by adverse economics, regulatory costs, and weak retention rather than durable growth. The combination of Medicaid attrition, ACA cost pressure, and CMS-related expense makes these exposures behave like dogs in the BCG Matrix: large enough to matter, but not strong enough to justify aggressive capital deployment.